Actionable and Equitable Testing with NxGen MDx
NxGen MDx is a medical laboratory dedicated to providing high-quality genetic screening and pathogen testing. We ensure that patients everywhere have access to equitable screens and tests that can improve their reproductive and overall health.
Are you pregnant or considering pregnancy?
Click on the appropriate link below to view a patient guide and learn more about genetic screening and testing options.
Carrier Screening
NxGen MDx’s intelligently curated Super Panel carrier screen is ethnicity-neutral and focuses on clinical actionability for every patient. Carrier screening allows couples at risk of passing along a genetic condition to pursue timely and appropriate management or treatment options before or during pregnancy.
“Carrier screening paradigms should be ethnic and population neutral and more inclusive of diverse populations to promote equity and inclusion.”
-The American College of Medical Genetics and Genomics1
Non-Invasive Prenatal Screening (NIPS)
Whole-genome sequencing provides results to 99.7% of patients using NxGen MDx’s NIPS. Our NIPS at NxGen MDx is appropriate for all pregnancies, regardless of age, ethnicity, BMI, or use of assisted reproductive technology.
“Cell-free DNA is the most sensitive and specific screening test for common fetal aneuploidies”
-The American College of Obstetricians and Gynecologists2
Hereditary Cancer Testing
NxGen MDx’s Hereditary Cancer Panel analyzes 32 genes recommended by the National Comprehensive Cancer Network (NCCN). Our streamlined support includes pre- and post-test genetic counseling and electronic tools to identify at-risk individuals.
“A hereditary cancer risk assessment is the key to identifying patients and families who may be at increased risk of developing certain types of cancer. Assessments should be performed by obstetrician–gynecologists or other obstetric–gynecologic care providers and should be updated regularly.”
-The American College of Obstetricians and Gynecologists3
Vaginosis Testing
Get comprehensive PCR testing for vaginitis that provides detailed information necessary for effective treatment with NxGen MDx’s Vaginosis Test. Patients receive results and information about antibiotic resistance in just 24 hours from sample receipt.
“STDs can complicate pregnancy and may have serious consequences for both a woman and her developing baby.”
-Centers for Disease Control and Prevention4
Urinary Tract Infection (UTI) Testing
Get comprehensive PCR testing for UTIs that provides detailed information necessary for effective treatment with NxGen MDx’s UTI Test. Patients receive results and information about antibiotic resistance in just 24 hours from sample receipt.
“All pregnant women should be screened for bacteriuria… as it is an important risk factor for pyelonephritis in this population.”5
We are here for you!
When you work with NxGen MDx you will have access to our experienced support staff as well as our team of board-certified genetic counselors.
Sources
1- Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021 Oct;23(10):1793–806.
2- American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet Gynecol. 2020 Oct;136(4):e48-e69. doi: 10.1097/AOG.0000000000004084. PMID: 32804883.
3- Hereditary cancer syndromes and risk assessment. ACOG Committee Opinion No. 793. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;134:e143–9.
4- STD Facts – STDs & Pregnancy Detailed Fact Sheet [Internet]. 2021 [cited 2022 Apr 7]. Available from: https://www.cdc.gov/std/pregnancy/stdfact-pregnancy-detailed.htm
5- Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med Sci. 2015 Mar 16;11(1):67–77.